Andrew is the President and Chief Financial Officer at Vaxcyte, Inc., and he brings over 20 years of financial, strategy, and operational experience in the biotech industry. At Vaxcyte, Andrew is responsible for leading the finance, corporate development and strategy, investor relations, corporate communications, human resources, IT, and facilities functions, and he helped lead Vaxcyte’s initial public offering in 2020. Prior to joining Vaxcyte, he served as Chief Financial Officer of Dermira, Inc. through its acquisition by Eli Lilly and Company in February 2020. During his tenure at Dermira, Andrew successfully led a series of private, public, and alternative financings and helped scale the company, including through its pivotal transition into a commercial-stage organization. Previously, Andrew served as Chief Financial Officer at several fast-growing biotech companies including Calistoga Pharmaceuticals, Inc., which was acquired by Gilead Sciences, Inc., and Facet Biotech Corporation, which was acquired by Abbott Laboratories. Earlier in his career, Andrew served as Chief Financial Officer of PDL BioPharma, Inc. until Facet Biotech was spun off from PDL BioPharma. Prior to joining Facet Biotech, he served as Chief Financial Officer for Neoforma, Inc., which was acquired by Global Healthcare Exchange, LLC. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He earned his B.A. in international politics and economics from Middlebury College and his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
This person is not in the org chart
This person is not in any teams